Pamela Blondin
Acute Care · Lewes, DENPI 1467820415
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,613 of the $5,616 with a category attached, or 64.3%. 16 manufacturers reported payments, led by Medtronic at 47.9% of the total. Reporting peaked in 2022 at $3,621 and has fallen 93.0% since, to $254 in 2025. Among acute care clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$555
- Pfizer$420
- Boehringer Ingelheim$332
- Johnson & Johnson$331
- Amgen$258
- plus $1K from 10 others
What the payments were for
- Travel & lodging$1,83433%
- Food & beverage$3,61364%
- Education$1693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 31 | $2,690 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $555 |
| Pfizer | 28 | $420 |
| Boehringer Ingelheim | 18 | $332 |
| Johnson & Johnson | 19 | $331 |
| Amgen | 15 | $258 |
| AstraZeneca | 13 | $242 |
| Novartis | 11 | $220 |
| Merck | 10 | $160 |
| Baxter Healthcare | 6 | $129 |
| Biotronik Inc. | 6 | $99 |
| E.r. Squibb & Sons, L.L.C. | 4 | $67 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Abbott | 2 | $34 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
How this compares
$5,616 in reported general payments places this provider in the 95th percentile of 26 acute care providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 282 | $359,840 |
| XareltoRivaroxaban | 78 | $95,490 |
| JardianceEmpagliflozin | 60 | $74,120 |
| FarxigaDapagliflozin Propanediol | 33 | $33,473 |
| Repatha SureclickEvolocumab | 29 | $24,814 |
| Metoprolol Succinate | 264 | $4,761 |
| Rosuvastatin Calcium | 77 | $1,550 |
| Atorvastatin Calcium | 106 | $1,156 |
| Ezetimibe | 44 | $1,004 |
| Flecainide Acetate | 30 | $989 |
| Nebivolol Hcl | 13 | $977 |
| Losartan Potassium | 102 | $913 |
| Amlodipine Besylate | 110 | $788 |
| Dilt-XrDiltiazem Hcl | 11 | $748 |
| Furosemide | 110 | $731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $420 | $359,840282 claims |
| Johnson & JohnsonXarelto | $331 | $95,49078 claims |
| Boehringer IngelheimJardiance | $332 | $74,12060 claims |
| AstraZenecaFarxiga | $242 | $33,47333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 26 acute care providers in Delaware.
Other acute care in Lewes
- Rachel FieldsLewes$3K
- Thomas TrobianoLewes$787
- Jill PetroneLewes$265
- Laura TolsonLewes$229
- Elizabeth FrederickLewes$28
- Jeannette DaumSeaford$6K
- Shanna AmorosoNewark$2K
- Youngja MooreNewark$1K
- Andrew VincentWilmington$1K
- Matthew FranklinNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.